Multiple endocrine neoplasia type 2 screening: Difference between revisions
Line 7: | Line 7: | ||
==Screening== | ==Screening== | ||
* The [[DNA]]-based testing of the c-[[RET proto-oncogene|''RET'' gene]] is recommended for children with increased risk of multiple endocrine neoplasia type 2. It can be easily performed on a [[blood]] sample at any age. It offers the opportunity for early identification of the c-''[[RET gene|RET]]'' germline [[mutation]]s, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant [[gene]] carriers makes possible the prevention and cure of [[medullary thyroid cancer]], by performing a prophylactic [[thyroidectomy]] before the clinical expression of the [[tumor]]. This test is also of importance to detect and thus, to reduce the risk of an unsuspected [[pheochromocytoma]]. | * The [[DNA]]-based testing of the c-[[RET proto-oncogene|''RET'' gene]] is recommended for children with increased risk of multiple endocrine neoplasia type 2. It can be easily performed on a [[blood]] sample at any age. It offers the opportunity for early identification of the c-''[[RET gene|RET]]'' germline [[mutation]]s, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant [[gene]] carriers makes possible the prevention and cure of [[medullary thyroid cancer]], by performing a prophylactic [[thyroidectomy]] before the clinical expression of the [[tumor]]. This test is also of importance to detect and thus, to reduce the risk of an unsuspected [[pheochromocytoma]].<ref name="Yip2003">{{cite journal|last1=Yip|first1=Linwah|title=Multiple Endocrine Neoplasia Type 2|journal=Archives of Surgery|volume=138|issue=4|year=2003|pages=409|issn=0004-0010|doi=10.1001/archsurg.138.4.409}}</ref> | ||
* Screening for multiple endocrine neoplasia type 2 include the following tests. | * Screening for multiple endocrine neoplasia type 2 include the following tests. | ||
{| | {| |
Revision as of 12:19, 24 June 2019
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 screening On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 screening |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the American Society of Clinical Oncology, screening for multiple endocrine neoplasia type 2 by RET gene testing is recommended for children with increased risk of multiple endocrine neoplasia type 2.
Screening
- The DNA-based testing of the c-RET gene is recommended for children with increased risk of multiple endocrine neoplasia type 2. It can be easily performed on a blood sample at any age. It offers the opportunity for early identification of the c-RET germline mutations, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant gene carriers makes possible the prevention and cure of medullary thyroid cancer, by performing a prophylactic thyroidectomy before the clinical expression of the tumor. This test is also of importance to detect and thus, to reduce the risk of an unsuspected pheochromocytoma.[1]
- Screening for multiple endocrine neoplasia type 2 include the following tests.
References
|